liquid biopsy

New Chronix Liquid Biopsy Test Could Save Doctors On Immunotherapy Costs

The liquid biopsy test uses proprietary algorithms to derive a copy number instability (CNI) score from sequencing circulating cell-free tumour DNA (cfDNA). Unlike conventional cancer molecular diagnostics, which seek to detect single mutations or rearrangements in the gene, Chronix’s technology takes a more holistic approach by looking at the genome – these gains and losses are representative of genomic instability caused by bad DNA repair and this can give an indication of how well a patient is recovering and their response to their cancer treatment.

The test has the potential to save healthcare providers on the high cost of immunotherapy drugs and any adverse side effects.

Read more